CHINARES PHARMA has announced the successful issuance of its inaugural medium-term note series.
The company's wholly-owned subsidiary has completed the domestic issuance of the first series of 2026 medium-term notes.
The notes carry a total principal value of RMB 1.0 billion with a three-year term and an annual coupon rate set at 1.53%.
Proceeds from the issuance are designated for supplementing working capital, repaying interest-bearing debt, and other purposes compliant with applicable laws and regulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments